CD274 and non-small cell lung carcinoma: Despite WL12’s low potency and inability to interfere with the therapeutic effects of α-PD-L1 antibodies in a patient, a radiolabeled WL12 for imaging was developed to determine the PD-L1 expression in non-small cell lung cancer (28).